Business Context and Reporting Period
Company: SciSparc Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: June 2023 (Report No. 2)
Date Filed: June 12, 2023
The filing discloses a corporate transaction entered into on June 7, 2023, involving a license and distribution agreement between SciSparc Ltd. and its subsidiary, SciSparc Nutraceuticals Inc. (in which the Company holds approximately a 51% equity interest).
Key Financial Metrics
The filing text does not provide specific financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics for the reporting period. The document focuses exclusively on the terms of a new commercial agreement.
Material Changes and Transaction Details
- Agreement Type: Exclusive license and distribution agreement for the Company's product, CannAmide™ (PEA oral tablets).
- Market: Amazon.com marketplace in Canada.
- Counterparty: SciSparc Nutraceuticals Inc. (51% owned subsidiary).
- Financial Terms: The Company will sell CannAmide™ to the subsidiary at cost price plus 3% of gross revenues.
- Term: 12 months, terminable by either party with 30 days' advance notice.
- Intellectual Property: All rights, title, and interest in IP associated with CannAmide™ remain the sole property of SciSparc Ltd.
Guidance, Outlook, and Risks
Management Commentary: The subsidiary is obligated to use its best efforts to maximize the sale of CannAmide™ under the agreement.
Risks and Contingencies: The filing notes customary provisions including representations, warranties, covenants, and indemnification of the Company by the subsidiary. No specific forward-looking financial guidance or risk factors regarding market performance were detailed in this specific text.
Investor Verification Checklist
- Verify the current equity ownership percentage of SciSparc Nutraceuticals Inc. to confirm the 51% interest stated.
- Review the press release (Exhibit 99.1) for additional details on the CannAmide™ product and market strategy.
- Monitor future filings for actual revenue recognition resulting from the 3% gross revenue markup.
- Confirm the status of the 12-month term and any potential early termination events.